Literature DB >> 6524897

Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusions.

D B Lakings, J M Friis, R J Brown, H R Allen.   

Abstract

The pharmacokinetics of cefpimizole (free acid equivalents of cefpimizole sodium), a broad-spectrum cephalosporin antibiotic, were determined after single- and multiple-dose 20-min intravenous infusions of 1, 2, and 4 g. The kinetics of single-dose administration of cefpimizole correspond to a two-compartment model with an average apparent volume of distribution of 20.0 +/- 3.5 liters, a distribution rate constant of 2.24 +/- 1.00 h-1, and a terminal rate constant of 0.358 +/- 0.036 h-1 (half-life, 1.9 h). The total body clearance was 118.6 +/- 20.2 ml/min. The primary route of elimination for cefpimizole was the renal route, with approximately 80% of the administered dose excreted as the parent compound. The elimination rate constant, as calculated from urinary excretion data, was 0.339 +/- 0.043 h-1, which is in close agreement with the terminal rate constant for plasma. Renal clearance of cefpimizole was 96.2 +/- 17.3 ml/min. Dose proportionality over the three dose levels was obtained from area under the plasma curve and cumulative urinary excretion data. The results of the multiple-dose study indicated that no apparent change in the distribution or elimination kinetics of cefpimizole occurred after the administration of 1-, 2-, and 4-g doses for 7 days, three times a day. The kinetics from the multiple-dose study were in close agreement with those from the single-dose study. No accumulation of cefpimizole occurred, and nondetectable levels was observed 24 h after administration of the last dose. Peaks that could be attributed to metabolites of cefpimizole were not observed during high-pressure liquid chromatographic analysis of either plasma or urine specimens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524897      PMCID: PMC180027          DOI: 10.1128/AAC.26.6.802

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Comparative pharmacokinetics of cefoperazone and cefamandole.

Authors:  S Srinivasan; E L Francke; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

2.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

3.  [Kinetics of cefotaxime in healthy subjects (author's transl)].

Authors:  J F Acar; J Guibert; M D Kitzis
Journal:  Nouv Presse Med       Date:  1981-02-26

4.  Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.

Authors:  L R Peterson; D N Gerding; L L Van Etta; J H Eckfeldt; T A Larson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

5.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Ceftazidime--a new extended-spectrum cephalosporin.

Authors:  D I Gozzard; A M Geddes; I D Farrell; S J Eykyn; I Phillips; R Wise; R M Brown
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

7.  High-performance liquid chromatographic methods for the determination of cefpimizole in plasma and urine.

Authors:  D B Lakings; J M Wozniak
Journal:  J Chromatogr       Date:  1984-06-08

8.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.

Authors:  R M Ings; J P Fillastre; M Godin; A Leroy; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

9.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

10.  Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency.

Authors:  W K Bolton; W M Scheld; D A Spyker; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more
  3 in total

1.  Tolerance and disposition of cefpimizole in normal human volunteers after intramuscular administration.

Authors:  E Novak; D B Lakings; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  In vitro comparative antimicrobial activity of cefpimizole against clinical isolates from five medical centers.

Authors:  R N Jones; L W Ayers; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

3.  Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administration.

Authors:  D B Lakings; E Novak; J M Friis; C M Lunan; L M Paxton
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.